Skip to main content
BerGenBio logo

BerGenBio — Investor Relations & Filings

Ticker · BGBIO ISIN · NO0013711713 LEI · 213800TYYFXKYF3V2A23 OL Manufacturing
Open in API
Filings indexed 961 across all filing types
Latest filing 2025-06-30 Capital/Financing Update
Country NO Norway
Listing OL BGBIO

About BerGenBio

https://www.bergenbio.com/

BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.

Recent filings

Filing Released Lang Actions
Announcement of fully underwritten rights issue
Capital/Financing Update Classification · 98% confidence The document is titled "Announcement of fully underwritten rights issue" and details a plan to raise approximately NOK 130 million through a rights issue for existing shareholders, contingent on a merger. This activity—raising capital through the issuance of new shares to existing shareholders via subscription rights—is explicitly covered by the definition of Capital/Financing Update (CAP). Although it involves shares, it is a financing event rather than a general share repurchase (POS) or a general share issue announcement (SHA), as the primary focus is the fundraising mechanism (rights issue) tied to a corporate action (merger). Since the document is an announcement detailing the terms of a financing event, CAP is the most appropriate classification.
2025-06-30 English
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
M&A Activity Classification · 99% confidence The document explicitly announces a 'proposed merger' between BerGenBio ASA and Oncoinvent ASA, detailing the exchange ratio, the subsequent 'fully underwritten rights issue' of NOK 130 million, and management changes. This content directly relates to significant corporate restructuring, financing activities, and potential takeover/merger proposals. The most fitting category is M&A Activity (TAR) for the merger announcement, or Capital/Financing Update (CAP) due to the prominent rights issue. Since the core event is the combination of two companies via a merger agreement, TAR is the primary classification. The document also mentions a presentation/webcast, but the substance is the transaction itself, not just the announcement of a report (RPA).
2025-06-30 English
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerGenBio_ASA_AGM_minutes_26_June_2025.pdf
AGM Information Classification · 100% confidence The document text is explicitly titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' (Minutes of the Annual General Meeting) and contains detailed records of resolutions passed regarding the election of the chairperson, approval of the 2024 Annual Report, election/re-election of board members, amendments to articles of association, election to the nomination committee, and approval of remuneration for various committees. The date mentioned is June 26, 2025, which aligns with an annual meeting schedule. This content perfectly matches the definition of materials shared during an Annual General Meeting.
2025-06-26 Norwegian
BerGenBio ASA - Minutes from the annual general meeting 2025
AGM Information Classification · 98% confidence The document title explicitly states "Minutes from the annual general meeting 2025". This directly corresponds to materials shared during the Annual General Meeting (AGM). Although it mentions the minutes are attached, the core content is the record of the AGM proceedings, making AGM-R the most specific classification over a general RPA or RNS. The length is short, but the content is the official record of the meeting itself.
2025-06-26 English
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
M&A Activity Classification · 99% confidence The document is an update from BerGenBio ASA regarding its ongoing strategic review process, which includes considering a potential sale or merger. It also announces the discontinuation of development activities for a drug (bemcentinib) and provides an estimate of remaining free cash. This content directly relates to significant corporate actions, potential transactions (sale/merger), and major strategic shifts. This aligns best with the 'M&A Activity' category (TAR), as the core subject is the strategic review aimed at a potential sale or merger. While it contains financial updates, the primary driver is the strategic transaction consideration. Given the nature of the announcement regarding a strategic review that includes 'a potential sale, merger, or other strategic transaction,' TAR is the most specific fit.
2025-06-03 English
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_BerGenBio_ASA_26_June_2025.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING" / "NOTICE OF ANNUAL GENERAL MEETING" for BerGenBio ASA. The content details the agenda for this meeting, including items like election of chairperson, approval of annual accounts, election of board members, amendments to articles of association, and approval of remuneration. This directly corresponds to the definition of materials shared during an Annual General Meeting.
2025-06-03 Norwegian

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.